Cannabidiol-based treatment receives marketing approval from EMA
EMA’s human medicines committee had cleared the cannabidiol oral solution, Epidiolex, for use to treat seizures.
List view / Grid view
News
Pharma companies to pay California $70m for drug delays
Teva Pharmaceuticals, Endo Pharmaceuticals and Teikoku will pay almost $70 million to the US state for delaying drugs to keep prices high.
PharmaLab 2019 – In times of changes
For the 7th time, PharmaLab, picks up the latest developments in regulations, quality control and assurance and in laboratory methods and systems.
Microrobots could be used to deliver drugs inside the body
Scientists have developed microrobots that can deliver medication to specific spots inside the body while being controlled from outside the patient.
EMA recommends Vitrakvi for EU marketing authorisation
The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi (larotrectinib), used to treat solid tumours with a specific gene mutation.
Three pharma companies accused of breaking competition law
The CMA alleges that a pharmaceutical company agreed to buy equal quantities of a pill from two drug suppliers, breaking competition law.
Pharma processing and packaging equipment market to see growth
The pharmaceutical processing and packaging equipment market is expected to witness a high increase during the forecast period (2019-2025).
Roche confirms cyber-attack from Winnti malware
The pharmaceutical company Roche has affirmed that it was hit by a Winnti cyber-attack, thought to be supported by the Chinese government.
RUXIENCE™ biosimilar granted approval from FDA
The FDA has approved RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan® (rituximab), for treatment of non-Hogkin’s lymphoma and other conditions.
Two lots of Kogenate® recalled due to mislabelling
Two lots of Kogenate® FS vials actually contain the FVIII hemophilia A treatment, Jivi®.
Bipartisan bill revealed to lower drug prices in US
The Senate Finance Committee has unveiled its bipartisan bill in an effort to lower drug prices, requiring drug manufacturers to justify price increases.
Warning issued to company for using unfounded CBD treatment claims
FDA issues warning to a company that claimed its CBD products can be used to treat cancer and Alzheimer's disease.
First patient enrolled on clinical study for denosumab biosimilar
An integrated Phase I/III trial has enrolled its first patient to test a biosimilar for denosumab to treat postmenopausal osteoporosis.
FDA approves nine generics for Lyrica drug
The FDA has announced that it has granted approval to the first nine generic drug applications for Pfizer’s Lyrica treatment.
New model could be used to predict shelf life of drugs
Researchers have developed a model that describes how antibody solutions separate into different phases and could be used to anticipate the stability and shelf-life of drugs.
